Skip to Content

Immunovant Inc IMVT

Morningstar Rating
$27.32 +0.03 (0.11%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IMVT is trading at a 10% premium.
Price
$27.17
Fair Value
$49.77
Uncertainty
Extreme
1-Star Price
$2,658.22
5-Star Price
$6.12
Economic Moat
Dfb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IMVT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.29
Day Range
$26.7627.71
52-Week Range
$18.1645.58
Bid/Ask
$25.65 / $28.00
Market Cap
$3.99 Bil
Volume/Avg
2.8 Mil / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
207

Comparables

Valuation

Metric
IMVT
PTGX
EQRX
Price/Earnings (Normalized)
13.22
Price/Book Value
6.443.370.97
Price/Sales
6.15
Price/Cash Flow
10.11
Price/Earnings
IMVT
PTGX
EQRX

Financial Strength

Metric
IMVT
PTGX
EQRX
Quick Ratio
13.1815.6118.43
Current Ratio
13.7015.7218.78
Interest Coverage
Quick Ratio
IMVT
PTGX
EQRX

Profitability

Metric
IMVT
PTGX
EQRX
Return on Assets (Normalized)
−44.70%51.28%−15.72%
Return on Equity (Normalized)
−49.06%56.32%−16.71%
Return on Invested Capital (Normalized)
−53.44%51.24%−21.31%
Return on Assets
IMVT
PTGX
EQRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
SvjdzlsdcPnpv$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
PnrdllffjCyflsl$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
ZycmbdwlKrxxgb$116.0 Bil
Moderna Inc
MRNA
VqyfcypDxrsb$51.1 Bil
argenx SE ADR
ARGX
RvgrbsttqWtl$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
TsjlzsyLtcvr$21.0 Bil
BioNTech SE ADR
BNTX
CsmqlrtzLmcjr$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
HxkpxcyFrygfm$15.9 Bil
United Therapeutics Corp
UTHR
RzxbzdgSmw$14.0 Bil
Incyte Corp
INCY
KsxkjvdmBmcjtz$12.5 Bil

Sponsor Center